Please take this 2-3 minutes survey, meant to gather insights on the first-line targeted treatments of EGFR mutation positive NSCLC. Lung cancer is one of the most common cancers. Globocan 2020 data shows, over 5% of cancer cases are lung cancers, constituting about 7.8% cancer deaths. A study presents startling facts that the Indian ethnicity population has a higher epidermal growth factor receptor (EGFR) mutation frequency of 23%, while that of Caucasian ethnicity is 10-15%. Further concern is indicated in Indian ethnicity, as non-smokers are more likely to carry EGFR mutations- 29% over smokers- 15.3%.
These facts hint that the targeted therapy can be an effective NSCLC management. 1,2 References: Sholl et al (2015) Yuan M, Huang LL, Chen JH, Wu J, Xu Q. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal transduction and targeted therapy. 2019…